Earnings Call for Q3FY21 of Caplin Point Laboratories
Conference Call with Caplin Point Laboratories Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.05-02-2021
05-02-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - OUTCOME OF THE BOARD MEETING
OUTCOME OF THE BOARD MEETING04-02-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
CONFERENCE CALL ON THURSDAY, FEBRUARY 04, 202102-02-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Intimation for Un-Audited Financial Results For The Quarter/Nine Months Ended December 31, 2020
CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2021 ,inter alia, to consider and approve and take on record the Un-audited Financial Results for the quarter/nine months ended December 31, 2020.29-01-2021
Caplin Point Labs gets USFDA nod for anticoagulant injection
Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application for Argatroban injection, 50 mg/50 ml (1 mg/ml), single-dose vial presentation, it said in a filing to BSE.22-01-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
PRESS RELEASE- DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,201522-01-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Shareholding for the Period Ended December 31, 2020
Caplin Point Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here19-01-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
PRESS RELEASE -DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015.18-01-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Vinod Kumar SDesignation :- Company Secretary and Compliance Officer13-01-2021